HLA-E and acute myeloid leukemia: In this direction, the CAR33-KLRC1ko-NK cell preparations from various allogenic donors induced a significantly increased cytotoxic efficacy already at low cell numbers against primary AML blast cells (HLA-E+) derived from a cohort of patients with either standard or high-risk molecular genotype (Fig. 5f, g)30.